Abstract:Dear Editor, Plexiform neurofibroma (PNF) is a particular subtype of benign nerve sheath tumors with a reticular growth pattern not respecting tissue borders and involving several nerve branches or fascicles. It is most commonly reported in patients with neurofibromatosis type-1 (NF-1) and represents in up to 30% of NF-1 patients (1,2). Other possible associations include schwannomatosis, multiple cutaneous schwannomas syndrome, and rarely neurofibromatosis type-2 (NF-2) (3). PNF develops as a result of tumor proliferation to all parts of the peripheral nervous system. It may cause functional and cosmetic impairment, pain, and a certain risk of malignant transformation in internal organs in some critical cases (4,5). Malignant peripheral nerve sheath tumors occur in about 10% of NF-1 patients (4,5). NF-1 is caused by mutations in the NF-1 tumor-suppressor gene, which encodes a GTPase-Activating Protein (GAP) that negatively regulates p21-RasNF1 (6). These patients have a predisposition to develop both benign and malignant tumors (6). Isolated or NF-1-associated cutaneous or superficial PNF, however, do not transform into their malignant counterpart (1). We report an isolated case of a plexiform PNF in a 16-year-old girl without NF-1. A-16-year-old Caucasian woman presented with a slow-growing exophytic nodule on her right flank. The tumor was asymptomatic, and tumor removal was requested for esthetic reasons. The patient was otherwise healthy. Her family history was negative for hereditary disorders. She was taking no medications at the time. On examination, a 1.8×1.6 cm large, slow-growing, and asymptomatic exophytic asymptomatic tumor was observed on the right flank (Figure 1). The primary suspicion was a complex nevus tumor type such as nevus sebaceous or nevus lipomatosus. The tumor was surgically removed, and the defect was closed by tissue expansion. Histology revealed a spindle-cell proliferation of S-100 positive cells without cellular atypia and myxoid stroma (Figure 2). The diagnosis of PNF was thus established. Healing was uneventful. There were no clinical signs of NF-1 or NF-2. We reported a case of PNF without NF-1 or NF-2. The diagnosis of an isolated PNF is a very rare event (7-10). In a large study from Lima lasting 33 years, only one isolated PNF not associated with NF-1 was observed. In this patient, PNF developed in the oral mucosa (7). An isolated PNF causing an auricular deformity has been previously observed in a 14-year-old boy (8). In India, a 11-year-old girl with an isolated PNF of the tongue was reported (9). Isolated PNFs are not necessarily limited to children and adolescents but may also occur later in life (10). The gold standard of treatment is surgical intervention. In case of unresectable and painful tumors, interferon alfa is a medical option (11). Other drugs are under evaluation, such as oral selumetinib, a selective inhibitor of MAPK kinase 1 and 2, AZD8055, an ATP-competitive "active-site" mTOR inhibitor, or a BromoDomain-containing protein 4-inhibitor (12,13). In conclusion, isolated PNF is a very rare observation. In case of impairment, surgery - whenever possible - is the preferred treatment option (8).

Integration of single-nuclei RNA-sequencing, spatial transcriptomics and histochemistry defines the complex microenvironment of NF1-associated plexiform neurofibromas

Spatial gene expression profiling unveils immuno-oncogenic programs of NF1-associated peripheral nerve sheath tumor progression

Pharmacological and Genomic Profiling of Neurofibromatosis Type 1 Plexiform Neurofibroma-Derived Schwann Cells

Schwann cell derived pleiotrophin stimulates fibroblast for proliferation and excessive collagen deposition in plexiform neurofibroma

Reduced PTPRS expression promotes epithelial-mesenchymal transition of Schwann cells in NF1-related plexiform neurofibromas

Multi-dimensional immunotyping of human NF1-associated peripheral nerve sheath tumors uncovers tumor-associated macrophages as key drivers of immune evasion in the tumor microenvironment

Combined CDK4/6 and ERK1/2 inhibition enhances anti-tumor activity in NF1-associated plexiform neurofibroma

EPCO-27. REVEALING TUMOR HETEROGENEITY AND IMMUNE MICROENVIRONMENT IN NF-1 GLIOMA BY SINGLE-CELL GENE EXPRESSION PROFILING

Distinctive mesenchymal-like neurofibroma stem cells shape NF1 clinical phenotypes controlled by BDNF microenvironment

Retracing RAS signaling by correlating protein expression in different subtypes of neurofibromatosis 1-associated nerve sheath tumors

Integrated genomic analysis of NF1-associated peripheral nerve sheath tumors: an updated biorepository dataset

Cell-free DNA ultra-low-pass whole genome sequencing to distinguish malignant peripheral nerve sheath tumor (MPNST) from its benign precursor lesion: A cross-sectional study

Stimulator of interferon gene facilitates recruitment of effector CD8 T cells that drive neurofibromatosis type 1 nerve tumor initiation and maintenance

Path-25. Consensus Recommendations For An Integrated Diagnostic Approach To Nerve Sheath Tumors Arising In The Setting Of Neurofibromatosis Type 1

Proof of Concept for Genome Profiling of the Neurofibroma/Sarcoma Sequence in Neurofibromatosis Type 1

Proteomic and Genetic Analysis Reveals Loss of EPB41L3 Related to the Tumorigenesis of Neurofibromatosis Type 1 and Type 2

PD-L1 Expression and Tumor Infiltrating Lymphocytes in Neurofibromatosis Type 1-Related Benign Tumors and Malignant Peripheral Nerve Sheath Tumors: an Implication for Immune Checkpoint Inhibition Therapy

Conditional deletion of Pten tumor suppressor gene and activation of K Ras oncogene result in the development of Neurofibromatoses

ERBB2 and ERBB3 Growth Factor Receptors, Neuregulin-1, CD44 and Ki-67 Proliferation Index in Neurofibromatosis Type 1-associated Peripheral Nerve Sheath Tumors

A Molecular Basis for Neurofibroma-Associated Skeletal Manifestations in NF1

Plexiform Neurofibroma Without Neurofibromatosis Type 1